Overview

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Linvemastat in Patients With Partially Controlled Asthma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, participants receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 16 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.

Phase:

PHASE2

Details

Lead Sponsor:

Foresee Pharmaceuticals Co., Ltd.

Collaborator:

QPS Holdings LLC